For over two decades, the U.S. Food and Drug Administration (FDA) has required a “black box” warning on hormone replacement therapy labels. This warning — the FDA’s most stringent safety notification — was based on clinical trial findings from the early 2000s. It influenced many women and clinicians to avoid HRT.
However, the FDA recently announced a historic shift: the removal of these broad warnings for most HRT products.
This decision marks a return to evidence-based medicine and reflects a reassessment of the previous clinical trial findings. It acknowledges that modern formulations and the “timing hypothesis” offer a far more favorable risk-benefit profile than previously understood.
A brief history: the WHI study and the black box warning
The origin of the HRT black box warning dates back to the July 2002 release of a troubling report. The initial results of the Women’s Health Initiative (WHI) showed a connection between HRT and serious health risks. This major federal study had been designed to test whether HRT could prevent chronic diseases in postmenopausal women.
Researchers had halted the study early after observing a small but significant increase in health risks for some participants. Women taking estrogen plus progestin showed increased risk of invasive breast cancer, heart disease, and stroke. Specifically, the 2002 data reported a 26% increase in breast cancer risk and a 41% increase in stroke risk.
Based on this information, the FDA placed black box warning labels on all menopause treatments that contain estrogen — including pills, patches, sprays, and creams. They warned that their use could increase the risk of uterine and breast cancer, strokes, and blood clots. The labels also warned about an increased risk of dementia for women over the age of 65.
Within three months of the publication of that report and the black box warning, 63% of women stopped taking hormone replacement therapy.
The timeline of events:
- July 2002: Initial WHI results published, sparking global alarm.
- January 2003: FDA mandated “black box” warning on all estrogen and progestin products, regardless of dose or delivery method.
- 2003–2020: HRT use plummeted by over 70%, as both patients and doctors avoided the therapy due to perceived risks.
The rationale for change: addressing “bad science” and “bureaucratic inertia”
“For more than two decades, bad science and bureaucratic inertia have resulted in women and physicians having an incomplete view of HRT. We are returning to evidence-based medicine and giving women control over their health again.”
— U.S. Health and Human Services Secretary Robert F. Kennedy, Jr. in a November 10, 2025 statement announcing the removal of the FDA black box warning
The FDA initiated removal of the boxed warnings following a review of the scientific literature, an expert panel, and a public comment period. The FDA’s current leadership, including Commissioner Dr. Marty Makary, noted that the initial WHI findings were often “distorted” and applied to the wrong populations.
These recent conclusions are based on 20+ years of scientific research clarifying the negative results of the 2002 WHI findings. Additional analyses of the WHI dataset and other studies have found critical factors not considered in the WHI report. It turns out that the type of HRT and the timing of treatment initiation make an important difference.
New concepts:
- The timing hypothesis and age: The average age of women in the 2002 WHI study was 63. That’s well past the typical onset of menopause, which is 45-55 years. Modern research shows that when women initiate HRT before they’re 60 or within 10 years of menopause onset, it significantly reduces all-cause mortality and offers cardiovascular protection.
- Formulations matter: The 2002 study used oral conjugated equine estrogen (CEE) and synthetic progestin (MPA). Today’s “gold standard” often involves transdermal estradiol (patches or gels) and micronized progesterone. These don’t carry the same risks of blood clots or breast cancer seen in the original synthetic oral versions.
- Distinction for vaginal estrogen: For years, low-dose vaginal estrogen — used locally for dryness and urinary health — carried the same scary warnings as systemic pills. The FDA has now recognized that these local treatments result in minimal systemic absorption. Regulators should never have grouped them with systemic therapies.
What changes on the label?
- Removal of boxed warnings: Language regarding cardiovascular disease, breast cancer, and probable dementia will be removed from the black box section.
- Systemic estrogen-alone exception: Women with a uterus use progesterone (in combination with estrogen) to protect the lining of the uterus. Thus, the warning for endometrial cancer will remain for systemic estrogen-alone products used by women who still have a uterus.
- End of the “lowest dose” mandate: The long-standing recommendation to use the “lowest effective dose for the shortest duration” is being removed to allow for individualized, long-term care.
What women should know now
The removal of the black box warning on HRT products is a victory for women’s health. The decision is in line with our knowledge of the risks and benefits of hormone replacement for menopausal symptoms. While HRT is not a “one-size-fits-all” miracle, the new labeling reflects a nuanced reality. For many women in the menopausal transition, the benefits of symptom relief and long-term bone and heart health far outweigh the risks.
The decision to take HRT should be individualized, taking into account the specific details of the woman’s health history and experience.
Learn more about the use of testosterone for menopause treatment and HRT after breast cancer. Visit Hormonally to discover more information on perimenopause and menopause. You can find more news on menopause here.
